SCHEMA

Mixed Access | Catalogue record last updated: 2026/06/26

The Schizophrenia Exome Sequencing Meta-analysis (SCHEMA) consortium is a large multi-site collaboration dedicated to aggregating, generating, and analyzing high-throughput sequencing data of schizophrenia patients to improve our understanding of disease architecture and advance gene discovery.


Scientific field(s): Genetics
Data type(s):

The Phase I dataset (GRCh37/hg19) contains the analysis of exomes from 24 248 cases and 97 322 controls, and de novo mutations from 3 402 parent-proband trios.

Data processing level: Aggregated
Study design: Case-control study
Method(s): Genome-wide genotyping

The Phase I of SCHEMA actively recruited from diverse global populations, and includes individuals of European, Latin American, East Asian, Ashkenazi Jewish, and African American ancestry. Because the sequence data was generated with various capture technologies over a span of seven years, methods were developed to reduce possible confounders. The first results provided genome-wide significant results associating ultra-rare protein-coding variants in individual genes to risk of schizophrenia. Later releases are planned with larger number of samples that will further increase power, and will be released here before any publication.

Condition(s)/Disease(s): Schizophrenia
Associated ressources:
  • 10.1038/s41586-022-04556-w: Singh, T. et al. Rare coding variants in 10 genes confer substantial risk for schizophrenia. Nature 604, 509–516 (2022).
Catalogue record last updated: June 26, 2026, midnight